April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Rosmarinic Acid Suppresses Retinal Neovascularization via Cell Cycle Arrest With Increase of p21WAF1 Expression
Author Affiliations & Notes
  • H. O. Jun
    NeuroVascular Coordination Research Center, College of Pharmacy and Research Institute of Pharmaceu, Seoul National University, seoul, Republic of Korea
  • J. H. Kim
    Department of Ophthalmology, Collegeof of Medicine, Seoul National University & Seoul Artificial Eye Center Clinical Research Institute, Seoul National University Hospital, seoul, Republic of Korea
  • J. H. Kim
    Department of Ophthalmology, Collegeof of Medicine, Seoul National University & Seoul Artificial Eye Center Clinical Research Institute, Seoul National University Hospital, seoul, Republic of Korea
  • B. J. Lee
    Department of Ophthalmology, Collegeof of Medicine, Seoul National University & Seoul Artificial Eye Center Clinical Research Institute, Seoul National University Hospital, seoul, Republic of Korea
  • K.-W. Kim
    NeuroVascular Coordination Research Center, College of Pharmacy and Research Institute of Pharmaceu, Seoul National University, seoul, Republic of Korea
  • Y. S. Yu
    Department of Ophthalmology, Collegeof of Medicine, Seoul National University & Seoul Artificial Eye Center Clinical Research Institute, Seoul National University Hospital, seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  H.O. Jun, None; J.H. Kim, None; J.H. Kim, None; B.J. Lee, None; K.-W. Kim, None; Y.S. Yu, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2930. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. O. Jun, J. H. Kim, J. H. Kim, B. J. Lee, K.-W. Kim, Y. S. Yu; Rosmarinic Acid Suppresses Retinal Neovascularization via Cell Cycle Arrest With Increase of p21WAF1 Expression. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2930.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate whether rosmarinic acid (RA) has an anti-angiogenic activity to retinal neovascularization in a mouse model of ROP, which is related to cell cycle arrest with Increase of p21WAF1

Methods: : In mice model of oxygen-induced retinopathy with or without intravitreal RA, neovascularization was measured through flourescein angiography using FITC-dextran and blood vessel count in cross section. To determine anti-angiogenic activity of RA to VEGF-induced in vitro angiogenesis, VEGF-induced proliferation and tube formation of retinal endothelial cells was evaluated with RA treatment. In addition, deguelin-induced retinal toxicity was evaluated as well. To investigate whether the anti-angiogenic activity of RA on retinal endothelial cells was related to the cell-cycle arrest, flow cytometry and p21WAF1 expression was evaluated.

Results: : RA significantly inhibited the proliferation of retinal endothelial cells in dose-dependent manner, and inhibited in vitro angiogenesis of tube formation. Interestingly, the anti-proliferative activity of RA on retinal endothelial cells was related to G2/M phase cell cycle arrest in a dose-dependent manner. With treatment of RA, retinal endothelial cells in G2/M phase increased whereas those in G0/G1 and S phases decreased, which was accompanied by increase of p21WAF1 expression in dose-dependent manner. Moreover, RA effectively suppressed retinal neovascularization in a mouse model of ROP, and showed no retinal toxicity.

Conclusions: : Our data suggests RA could be a potent inhibitor of retinal neovascularization and may be applied in the treatment of other vasoproliferative retinopathies.

Keywords: drug toxicity/drug effects • retinal neovascularization • retinopathy of prematurity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×